Home › Overweight › NCT07767175
A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity
RecruitingPhase 1Healthy volunteers welcome
A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0721-8060 in Healthy Adult Participants Living With Overweight or Obesity
Who can join
Ages 18 to 55 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Male or female (sex at birth). * Age 18-55 years (both inclusive) at the time of signing informed consent. * Body Mass Index (BMI) 27.0-34.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening, with overweight due to excess adipose tissue as judged by the investigator. * Considered eligible based on medical history, physical examination, vital signs, electrocardiogram and clinical laboratory tests at screening, as judged by the investigator. Exclusion Criteria: * Known or suspected hypersensitivity to study intervention(s) or related products. * Previous randomisation in this study. * History of allergies (with the exception of seasonal allergies) or history of anaphylactic reactions. * Female who is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not using adequate contraception. * Current participation (signed informed consent) in any other interventional clinical study. * Exposure to an investigational medicinal product within 30 days or five half-lives of that product (whichever is longer) before screening. * Any disorder, unwillingness or inability which, in the investigator's opinion, might jeopardise participant safety or compliance with the protocol. * Glycated haemoglobin (HbA1c) greater than or equal to (≥) 6.5 percentage (%) (48 millimoles per mole \[mmol/mol\]) at screening.
About the study
The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.
What is being tested
- NNC0721-8060 (drug)
- Semaglutide (drug)
- Placebo (drug)
Sponsor: Novo Nordisk A/S · Participants: 142 · Started: Aug 12, 2026
Contact the study team
- Novo Nordisk · Phone: (+1) 866-867-7178
Official record on ClinicalTrials.gov — NCT07767175
Locations in the U.S.
| Kansas | ICON Early Phase Services, LLC, Lenexa |
| Texas | ICON, San Antonio (Not yet recruiting) |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.